The Liver Keeps the Score: Americans Are Drinking Less, but Alcohol-Associated Liver Disease May Lag
Drinking fell for the first time since COVID-19, but not for adults 50 to 64. Hepatologists explain what clinicians can do to close the gap.
News|Videos|April 8, 2026
Q1 2026 Recap: Hepatology News and Updates
Author(s)Abigail Brooks, MA
Fact checked by: Victoria Johnson
Q1 2026 hepatology highlights include advances in MASH, hepatitis B, gene editing for AATD, and the first approved therapy for pruritus in PBC.
Advertisement
Advertisement
The first quarter of 2026 brought a wave of momentum in hepatology, with advances spanning metabolic liver disease, viral hepatitis, rare genetic disorders, and symptom-directed care. From regulatory designations to late-stage clinical data and US Food and Drug Administration (FDA) approvals, the landscape continues to evolve rapidly, with a growing emphasis on disease modification and precision-based approaches.
Related to this article
As drinking declines, Stevan Gonzalez, MD, Frances Lee, MD, and Brian Lee, MD, on the lingering burden of alcohol-associated liver disease.
Approved US PFIC drugs treat pruritus. The researcher behind a therapy targeting BSEP on diagnosis, data, and what comes next.
Strong recommendations cover carvedilol or banding for varices, semiannual HCC surveillance, vaccines, and smoking cessation.
Hepatology in September 2026: brelovitug meets phase 3 AZURE-1 endpoint in hepatitis D, plus new US alcohol use data and ALD insights.
Nephrology in Q3 2026: FDA approvals for atacicept, iptacopan, finerenone, and obinutuzumab, plus 2-year IgAN data and CKD screening.
Q3 2026 dermatology recap: FDA approvals in dermatomyositis, adolescent alopecia areata, and sBCC, plus new psoriasis and vitiligo findings.
Florence Schleich, MD, PhD, explains how exacerbation phenotypes and useful biomarkers shift across anti-IL-5, anti-IL-5R, and anti-TSLP therapies.
Advertisement
Advertisement